Progress in the treatment of childhood immune thrombocytopenia / 国际儿科学杂志

ABSTRACT

Immune thrombocytopenia(ITP)is an autoimmune disease which causes a series of bleeding manifestations due to thrombocytopenia.The pathogenesis is not clear.The first-line drugs include glucocorticoids and intravenous immunoglobulin(IVIG). The second-line drugs include thrombopoietin, rituximab, etc.Immunosuppressants and splenectomy need to strictly grasp the indications.New drugs in clinical trials include spleen complex kinase inhibitors, cytokines, etc.Combined therapy will further improve the prognosis of chronic, refractory ITP in children.The review of the progress of ITP treatment in children provides a reference for clinical standard diagnosis and treatment.